Active fraction having anti-cancer and anti-metastasis isolated from leaves and stems of ginseng
Provided is a composition that contains, as an active ingredient, an extract or polysaccharides separated from the leaves and/or stems of plants belonging to Panax genus, for an anticancer drug or its adjuvant, having an effect on the activity of hematopoiesis enhancement, cancer metastasis inhibition, bone marrow defense, etc. . . . , and a process for preparation of the extract from the leaves and/or stems of plants belonging to Panax genus.
1. An anticancer composition comprising
as an active ingredient an extract isolated by
heating the leaves and/or stems of plants belonging to Panax quinquefolium and/or Panax ginseng to obtain a crude extract solution;
filtering the crude extract solution;
optionally, concentrating the filtrate; and
precipitating the filtrate with alcohol or acetone, wherein the precipitate is the extract, and
wherein the extract comprises polysaccharides which contain KDO (2-keto-3-deoxyocturosonic acid) and have a molecular weight of 6,000-340,000 Da.
2. The composition according to claim 1 , wherein the polysaccharides comprise neutral sugar, and uronic acid.
3. The composition according to claim 2 , wherein the sugar composition of the polysaccharides includes rhamnose, fucose, arabinose, xylose, mannose, glucose, galactose, galacturonic acid, glucuronic acid, KDO, and DHA.
4. The composition according to claim 1 , wherein the composition has an effect on the inhibition of the proliferation and metastasis of cancer cells.
5. The composition according to claim 1 , wherein the composition has a therapeutic and/or prophylactic effect on solid cancers of epithelial or non-epithelial origin.
6. The composition according to claim 1 , wherein the composition has a therapeutic and/or prophylactic effect on cancer.
7. The composition according to claim 1 , wherein the composition is effective for at least one of the hematopoiesis enhancement, bone marrow defense, immune enhancement, radiation treatment aid, anti-virus, and anti-germ activities.
8. The composition according to claim 7 , wherein the composition has the activity of hematopoiesis enhancement.
9. The composition according to claim 7 , wherein the composition has the activity of reducing the side effects of general anticancer drugs, including the decrease of leucocytes and thrombocytes.
10. The composition according to claim 7 , wherein the composition has the activity of protecting bone marrow and spleen from radiation.
11. The composition according to claim 7 , wherein the composition has the activity for enhancement of the activation of immune system cells including NKT cells, NK cells, macrophages, T cells and B cells.
12. The composition according to claim 7 , wherein the composition activates NKT cells, NK cells, macrophages, T cells and B cells to secrete tumor necrosis factors, gamma interferon and interleukin 1, being anticancer materials, thereby slowing anticancer, anti-microbial and/or anti-virus activity.
13. The composition according to claim 1 , wherein the composition further comprises an anticancer drug(s) and/or an adjuvant(s) therefore.
14. The composition according to claim 13 , wherein the anticancer drug is Taxol, Cisplatin, cyclophosphamide, or two or more of the foregoing.
15. The composition according to claim 1 , wherein the composition further comprises a carrier or excipient.
16. The composition according to claim 15 , wherein the carrier or excipient is the pharmaceutically acceptable one in the form of drink or food.
17. A method of treating cancer comprising administering the composition according to claim 1 in conjunction with an anticancer drug or with radiation therapy to a patient.
18. The method according to claim 17 , wherein the anticancer drug is Taxol, Cisplatin, cyclophosphamide, or two or more of the foregoing.
19. The composition according to claim 1 further comprising a pharmaceutically acceptable carrier or excipient.
20. The composition according to claim 19 , wherein the composition further comprises an antacid.
21. The composition according to claim 20 , wherein the composition is in the form of one of tablet, powder, hard or soft capsule, suspension, solution for injection, emulsion, and non-oral administration form for single or multiple dosage.
22. The composition according to claim 19 , wherein the dosage of the active ingredient is in the range of 0.1-6,000 mg/day based upon the average body weight of an adult.
23. The composition according to claim 2 , wherein the polysaccharides have a neutral sugar content of 30-80% and a uronic acid content of 10-60%.
24. A method for treating a cancer comprising administering the composition according to claim 1 to a patient.